Summary
Isotope-labeled amino acids are highly valuable and versatile tools to tackle complex biological questions and to accelerate research and therapeutic development. Current production processes are, however, low-yielding, expensive and time-intensive, and cannot be applied to all amino acids, leading to missed therapeutic opportunities and inefficient use of resources. We have addressed these limitations and developed an innovative and more efficient method to produce such isotope-labeled amino acids. Our new technology is fully scalable, substantially undercuts industry production costs, and provides access to products currently not available.
The main objective of this project is to advance this technology to a commercializable stage that will enable us to distribute these valuable tools globally. This requires further proof-of-concept data and expansion and optimization of our protocols to bring it to industry standards and scale. This, in turn, will strengthen our intellectual property position, which is crucial for establishing a spin-off company. Anticipated outcomes of successful commercialization of our technology include several economic benefits for the EU, strengthening EU’s leadership in biotechnology and innovation, and –most importantly– technological advancements that will create new research avenues, improve research translation and disease management, and lead to an overall improvement of health and well-being.
The main objective of this project is to advance this technology to a commercializable stage that will enable us to distribute these valuable tools globally. This requires further proof-of-concept data and expansion and optimization of our protocols to bring it to industry standards and scale. This, in turn, will strengthen our intellectual property position, which is crucial for establishing a spin-off company. Anticipated outcomes of successful commercialization of our technology include several economic benefits for the EU, strengthening EU’s leadership in biotechnology and innovation, and –most importantly– technological advancements that will create new research avenues, improve research translation and disease management, and lead to an overall improvement of health and well-being.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/963875 |
| Start date: | 01-11-2020 |
| End date: | 31-10-2022 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Isotope-labeled amino acids are highly valuable and versatile tools to tackle complex biological questions and to accelerate research and therapeutic development. Current production processes are, however, low-yielding, expensive and time-intensive, and cannot be applied to all amino acids, leading to missed therapeutic opportunities and inefficient use of resources. We have addressed these limitations and developed an innovative and more efficient method to produce such isotope-labeled amino acids. Our new technology is fully scalable, substantially undercuts industry production costs, and provides access to products currently not available.The main objective of this project is to advance this technology to a commercializable stage that will enable us to distribute these valuable tools globally. This requires further proof-of-concept data and expansion and optimization of our protocols to bring it to industry standards and scale. This, in turn, will strengthen our intellectual property position, which is crucial for establishing a spin-off company. Anticipated outcomes of successful commercialization of our technology include several economic benefits for the EU, strengthening EU’s leadership in biotechnology and innovation, and –most importantly– technological advancements that will create new research avenues, improve research translation and disease management, and lead to an overall improvement of health and well-being.
Status
CLOSEDCall topic
ERC-2020-POCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
